CY2293B1 - Slow-release pharmaceutical formulations containing mizolastin - Google Patents

Slow-release pharmaceutical formulations containing mizolastin

Info

Publication number
CY2293B1
CY2293B1 CY0200052A CY0200052A CY2293B1 CY 2293 B1 CY2293 B1 CY 2293B1 CY 0200052 A CY0200052 A CY 0200052A CY 0200052 A CY0200052 A CY 0200052A CY 2293 B1 CY2293 B1 CY 2293B1
Authority
CY
Cyprus
Prior art keywords
mizolastin
slow
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
CY0200052A
Other languages
English (en)
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of CY2293B1 publication Critical patent/CY2293B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0200052A 1996-03-04 2002-08-26 Slow-release pharmaceutical formulations containing mizolastin CY2293B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (1)

Publication Number Publication Date
CY2293B1 true CY2293B1 (en) 2003-07-04

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0200052A CY2293B1 (en) 1996-03-04 2002-08-26 Slow-release pharmaceutical formulations containing mizolastin

Country Status (35)

Country Link
US (2) US6165507A (ko)
EP (1) EP0906101B1 (ko)
JP (2) JP2000512617A (ko)
KR (1) KR100369888B1 (ko)
CN (1) CN1112929C (ko)
AR (1) AR006082A1 (ko)
AT (1) ATE219365T1 (ko)
AU (1) AU725494B2 (ko)
BG (1) BG63451B1 (ko)
BR (1) BR9707827A (ko)
CA (1) CA2247405C (ko)
CO (1) CO4780020A1 (ko)
CY (1) CY2293B1 (ko)
CZ (1) CZ291418B6 (ko)
DE (1) DE69713505T2 (ko)
DK (1) DK0906101T3 (ko)
EE (1) EE03511B1 (ko)
ES (1) ES2177942T3 (ko)
FR (1) FR2745500B1 (ko)
HK (1) HK1017999A1 (ko)
HU (1) HU227472B1 (ko)
IL (1) IL126050A (ko)
IN (1) IN187739B (ko)
NO (1) NO315841B1 (ko)
NZ (1) NZ331947A (ko)
OA (1) OA10854A (ko)
PL (1) PL189813B1 (ko)
PT (1) PT906101E (ko)
RU (1) RU2173997C2 (ko)
SK (1) SK282112B6 (ko)
TR (1) TR199801574T2 (ko)
TW (1) TW491711B (ko)
UA (1) UA49004C2 (ko)
WO (1) WO1997032584A1 (ko)
ZA (1) ZA971830B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
DK1322158T3 (da) * 2000-10-02 2012-11-19 Usv Ltd Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP2564833B1 (en) 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
HUP9902458A2 (hu) 2000-05-28
ZA971830B (en) 1997-09-04
NO315841B1 (no) 2003-11-03
SK121098A3 (en) 1999-01-11
JP2007182451A (ja) 2007-07-19
NO984035D0 (no) 1998-09-02
TR199801574T2 (xx) 1998-11-23
IL126050A0 (en) 1999-05-09
PL328763A1 (en) 1999-02-15
ATE219365T1 (de) 2002-07-15
FR2745500A1 (fr) 1997-09-05
CA2247405A1 (en) 1997-09-12
NO984035L (no) 1998-10-22
KR100369888B1 (ko) 2003-05-17
BG102692A (en) 1999-04-30
EP0906101A1 (fr) 1999-04-07
EP0906101B1 (fr) 2002-06-19
DE69713505D1 (de) 2002-07-25
HUP9902458A3 (en) 2002-11-28
CO4780020A1 (es) 1999-05-26
WO1997032584A1 (fr) 1997-09-12
CN1112929C (zh) 2003-07-02
BG63451B1 (bg) 2002-02-28
RU2173997C2 (ru) 2001-09-27
HK1017999A1 (en) 1999-12-10
PT906101E (pt) 2002-09-30
HU227472B1 (en) 2011-07-28
DE69713505T2 (de) 2003-02-13
EE9800275A (et) 1999-02-15
PL189813B1 (pl) 2005-09-30
CZ279198A3 (cs) 1999-01-13
BR9707827A (pt) 1999-07-27
CA2247405C (en) 2004-04-20
US20050202089A1 (en) 2005-09-15
NZ331947A (en) 2000-03-27
OA10854A (fr) 2003-02-05
TW491711B (en) 2002-06-21
FR2745500B1 (fr) 1998-04-03
IN187739B (ko) 2002-06-15
IL126050A (en) 2004-05-12
ES2177942T3 (es) 2002-12-16
UA49004C2 (uk) 2002-09-16
US6165507A (en) 2000-12-26
AU1930097A (en) 1997-09-22
JP2000512617A (ja) 2000-09-26
CN1212624A (zh) 1999-03-31
SK282112B6 (sk) 2001-11-06
EE03511B1 (et) 2001-10-15
AR006082A1 (es) 1999-08-11
DK0906101T3 (da) 2002-10-14
AU725494B2 (en) 2000-10-12
KR19990087387A (ko) 1999-12-27
CZ291418B6 (cs) 2003-03-12

Similar Documents

Publication Publication Date Title
EG23826A (en) Pharmaceutical formulations
GB9713149D0 (en) Pharmaceutical formulations
GB9408117D0 (en) Pharmaceutical formulations
AP9600883A0 (en) Pharmaceutical formulations
SG79255A1 (en) Pharmaceutical formulations
ZA951781B (en) Pharmaceutical formulations
ZA982872B (en) Pharmaceutical formulation
HUP9902458A3 (en) Slow-release pharmaceutical formulations containing mizolastin
GB9709739D0 (en) Pharmaceutical formulation
HUP0003528A3 (en) Pharmaceutical compositions containing dihydropolyprenols
ZA96392B (en) Pharmaceutical formulations
SI0906101T1 (en) Slow-release pharmaceutical formulations containing mizolastin
GB9413542D0 (en) Pharmaceutical formulations
GB9500978D0 (en) Pharmaceutical formulations
GB9606372D0 (en) Pharmaceutical formulations
GB9621531D0 (en) Pharmaceutical formulations
GB9703607D0 (en) Pharmaceutical formulations
GB9603141D0 (en) Pharmaceutical formulation
GB9813452D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations
GB9807556D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9820837D0 (en) Pharmaceutical formulations